These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Solving the overdiagnosis dilemma. Esserman L; Thompson I J Natl Cancer Inst; 2010 May; 102(9):582-3. PubMed ID: 20413743 [No Abstract] [Full Text] [Related]
23. PSA screening: a view from the front lines. North York General-Branson Practice-Based Small Group. Greiver M; Rosen N CMAJ; 2000 Mar; 162(6):789-90. PubMed ID: 10750465 [No Abstract] [Full Text] [Related]
24. [The National Board of Health and Welfare's guidelines for prostatic cancer care. PSA test screening--only for well-informed men]. Bratt O; Damber JE; Kärvinge C; Malm T; Hensjö LO; Hyttsten E Lakartidningen; 2008 Feb 20-26; 105(8):524-8. PubMed ID: 18363292 [No Abstract] [Full Text] [Related]
25. How valuable is prostate-specific antigen screening? Handler S Minn Med; 1996 Jun; 79(6):2. PubMed ID: 8692130 [No Abstract] [Full Text] [Related]
26. Prostate cancer--the snowball is rolling. Ruutu M; Salo J; Nordling S; Rannikko S Ann Chir Gynaecol; 1999; 88(1):5-8. PubMed ID: 10230675 [No Abstract] [Full Text] [Related]
27. Early diagnosis of prostate cancer: the continuing debate on the impact on mortality. Höltl W; Lunglmayr G Wien Klin Wochenschr; 2005 Jul; 117(13-14):440-1. PubMed ID: 16091868 [No Abstract] [Full Text] [Related]
28. [Screening for prostate cancer: results from the first screening round in the French population of the ERSPC trial]. Richard F Prog Urol; 2009 Jul; 19(7):499-500. PubMed ID: 19559381 [No Abstract] [Full Text] [Related]
29. [The PSA test--abomination or blessing? Longer follow up necessary to get an answer]. Aus G Lakartidningen; 2010 Feb 17-23; 107(7):422-3. PubMed ID: 20384073 [No Abstract] [Full Text] [Related]
30. [Based on current knowledge the introduction of the PSA screening for prostatic cancer is unethical]. Krantz I; Sachs L; Ahlberg BM; Nordin P; Nilstun T Lakartidningen; 2005 Sep 5-11; 102(36):2498-500. PubMed ID: 16196436 [No Abstract] [Full Text] [Related]
31. [Prostate-specific antigen--the most important cancer marker. Diagnostics and follow up of prostatic cancer have changed]. Bratt O; Björk T Lakartidningen; 2007 Nov 14-20; 104(46):3460-4. PubMed ID: 18072615 [No Abstract] [Full Text] [Related]
32. [No evidence that lowered PSA reference levels will help us detect those cases of prostatic cancer that will lead to morbidity and mortality]. Malmström PU Lakartidningen; 2005 Jun 27-Jul 10; 102(26-27):2005; author reply 2005. PubMed ID: 16044760 [No Abstract] [Full Text] [Related]
33. [Advancements in PSA-based screening for prostate cancer]. Ito K Rinsho Byori; 2004 Jul; 52(7):611-7. PubMed ID: 15344561 [TBL] [Abstract][Full Text] [Related]
35. [PSA related screening of prostate cancer. Panic or improvement?]. Fornara P; Jurczok A Aktuelle Urol; 2004 Feb; 35(1):43-8. PubMed ID: 14997414 [TBL] [Abstract][Full Text] [Related]
36. Prostate cancer and prostate-specific antigen: facts, figures and commentary. Chambers DC J Insur Med; 1993; 25(3):336-40. PubMed ID: 10146433 [No Abstract] [Full Text] [Related]
37. Early stage prostate cancer--do we have a problem with over-detection, overtreatment or both? Carroll PR J Urol; 2005 Apr; 173(4):1061-2. PubMed ID: 15758699 [No Abstract] [Full Text] [Related]
38. Re: The prostate specific antigen era in the United States is over for prostate cancer: what happened in the last 20 years? Rosser CJ; Parker A J Urol; 2005 Sep; 174(3):1154-5; author reply 1155-6. PubMed ID: 16094093 [No Abstract] [Full Text] [Related]
39. Prostate cancer--more information and more questions. Dall'Era M; Carroll PR J Urol; 2007 May; 177(5):1607-8. PubMed ID: 17437768 [No Abstract] [Full Text] [Related]
40. Prostate cancer: a review of common underwriting problems, Part 1. Richie RC; Swanson JO J Insur Med; 2004; 36(3):242-54. PubMed ID: 15495440 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]